Kasivisvanathan, V;
Lindsay, J;
Rakshani-Moghadam, S;
Elhamshary, A;
Kapriniotis, K;
Kazantzis, G;
Syed, B;
... UCLH study group collaborators; + view all
(2020)
A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site.
International Journal of Surgery
, 84
pp. 57-65.
10.1016/j.ijsu.2020.10.019.
Preview |
Text
A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site.pdf - Published Version Download (575kB) | Preview |
Abstract
BACKGROUND: Two million non-emergency surgeries are being cancelled globally every week due to the COVID-19 pandemic, which will have a major impact on patients and healthcare systems. METHODS: During the peak of the pandemic in the United Kingdom, we set up a multicentre cancer network amongst 14 National Health Service institutions, performing urological, thoracic, gynaecological and general surgical urgent and cancer operations at a central COVID-19 cold site. This is a cohort study of 500 consecutive patients undergoing surgery in this network. The primary outcome was 30-day mortality from COVID-19. Secondary outcomes included all-cause mortality and post-operative complications at 30-days. RESULTS: 500 patients underwent surgery with median age 62.5 (IQR 51-71). 65% were male, 60% had a known diagnosis of cancer and 61% of surgeries were considered complex or major. No patient died from COVID-19 at 30-days. 30-day all-cause mortality was 3/500 (1%). 10 (2%) patients were diagnosed with COVID-19, 4 (1%) with confirmed laboratory diagnosis and 6 (1%) with probable COVID-19. 33/500 (7%) of patients developed Clavien-Dindo grade 3 or higher complications, with 1/33 (3%) occurring in a patient with COVID-19. CONCLUSION: It is safe to continue cancer and urgent surgery during the COVID-19 pandemic with appropriate service reconfiguration.
Archive Staff Only
 |
View Item |
